WASHINGTON, Dec. 17, 2015 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it
has appointed Gian Piero Reverberi
to the role of Senior Vice President, Acting Chief Commercial
Officer and European General Manager. Mr. Reverberi was
previously Vanda's Senior Vice President and European General
Manager and replaces Tom Gibbs,
Vanda's former Senior Vice President and Chief Commercial Officer,
who has resigned from Vanda to pursue a new opportunity.
"I would like to congratulate Gian
Piero in his new role, and wish him much success as we
continue to drive Vanda on a strong growth trajectory. I also
would like to thank Tom for his leadership and significant
contributions over the past year and wish him success as he pursues
his next opportunity," said Mihael H.
Polymeropoulos MD, President and CEO, Vanda Pharmaceuticals.
Prior to joining Vanda, Mr. Reverberi served as Senior Vice
President, International Specialty Pharma at Shire Pharmaceuticals,
with responsibility for Shire's specialty pharma business in EMEA,
Canada, Australia, Japan, Asia
Pacific and Latin America.
In addition to his International Specialty Pharma responsibilities,
from 2009-2013, Mr. Reverberi led Shire's Internal Medicine Global
Business Unit where his responsibilities included the management of
the US Sales and Marketing teams. Prior to this position, he
was General Manager, Italy at
Shire. Before joining Shire, Mr. Reverberi spent 10 years with Eli
Lilly in Italy and the U.S. where
he held several commercial positions including Business Unit
Director (Diabetes Care) in Italy,
District Manager and Business Development Leader in the U.S.
Earlier in his career, Mr. Reverberi held finance positions in the
U.S. and Italy with both Eli Lilly
and IBM. Mr. Reverberi received his degree in Economics and
Business Administration from Sapienza University of Rome and a Master in Business Administration
from SDA Bocconi in Milan.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company
focused on the development and commercialization of novel therapies
addressing high unmet medical needs. For more on Vanda,
please visit www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release are "forward-looking
statements" under the securities laws. Forward-looking statements
are based upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking statements include, among
others, Vanda's assumptions regarding its growth trajectory and
other factors that are described in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of Vanda's annual report on Form
10-K for the fiscal year ended December 31,
2014 and quarterly report on Form 10-Q for the quarter ended
September 30, 2015, which are on file
with the SEC and available on the SEC's website at www.sec.gov. In
addition to the risks described above and in Vanda's annual report
on Form 10-K and quarterly reports on Form 10-Q, other unknown or
unpredictable factors also could affect Vanda's results. There can
be no assurance that the actual results or developments anticipated
by Vanda will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on, Vanda.
Therefore, no assurance can be given that the outcomes stated in
such forward-looking statements and estimates will be achieved.
Corporate Contact:
Jim
Kelly
Senior Vice President and Chief Financial
Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Assistant
Vice President
Makovsky
(212)508-9642
llandsman@makovsky.com
SOURCE Vanda Pharmaceuticals Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-appoints-gian-piero-reverberi-as-acting-chief-commercial-officer-300194805.html
SOURCE Vanda Pharmaceuticals Inc.